Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/TEZSPIRE shows lasting symptom and disease improvement in eosinophilic esophagitis through 52 weeks
AMGN
$439.83
+$2.84 +0.65%

TEZSPIRE shows lasting symptom and disease improvement in eosinophilic esophagitis through 52 weeks

Company Fundamentals
27 Aug 2026
PRNewsWire
View Source
Bullish
pluang ai news

Amgen and AstraZeneca announced that TEZSPIRE (tezepelumab-ekko) demonstrated significant and sustained improvements in eosinophilic esophagitis (EoE) patients in the Phase 3 CROSSING trial, with benefits maintained through 52 weeks. The drug improved both histologic remission and swallowing difficulties, addressing a condition that affects over 470,000 people in the U.S. and often resists current treatments. These results support TEZSPIRE's potential as a new treatment option for EoE, expanding its use beyond severe asthma and nasal polyps. Full data will be shared with regulators and the medical community soon.

More News (AMGN)

VanEck Biotech ETF (BBH) is a Buy with strong growth potential from leading biotech firms.

VanEck Biotech ETF (BBH) is a Buy with strong growth potential from leading biotech firms.

The VanEck Biotech ETF (BBH) is recommended as a Buy due to its focused exposure to top biotech companies like Amgen, Gilead, and Vertex, which are entering a new growth phase. These firms support capital growth through diverse drug pipelines, strong...

Analyst Insights
Bullish
3 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App